| Literature DB >> 34414307 |
Jesse Dawson1, Áine Merwick2, Alastair Webb3, Martin Dennis4, Julia Ferrari5, Ana Catarina Fonseca6.
Abstract
Prevention of early recurrent ischaemic stroke remains a priority in people with TIA or ischaemic stroke. A number of trials have recently been completed assessing the efficacy of short-term dual antiplatelet therapy (DAPT) versus single antiplatelet therapy early after minor or moderate stroke or high-risk TIA. We present an Expedited Recommendation for use of dual antiplatelet therapy early after ischaemic stroke and TIA on behalf of the ESO Guideline Board. We make a strong recommendation based on high quality of evidence for use of 21-days of dual antiplatelet therapy with aspirin and clopidogrel in people with a non-cardioembolic minor ischaemic stroke or high-risk TIA in the past 24 hours. We make a weak recommendation based on moderate quality evidence for 30-days of dual antiplatelet therapy with aspirin and ticagrelor in people with non-cardioembolic mild to moderate ischaemic stroke or high-risk TIA in the past 24 hours. © European Stroke Organisation 2021.Entities:
Keywords: Stroke; TIA; antiplatelets
Year: 2021 PMID: 34414307 PMCID: PMC8370061 DOI: 10.1177/23969873211027006
Source DB: PubMed Journal: Eur Stroke J ISSN: 2396-9873